Evaluating the Prevalence and Predictors of Thyroid Dysfunction in Patients with Type 2 Diabetes Mellitus

Dear Editor, We would like to sincerely thank the entire team of the Journal (Medical Journal of Dr. D. Y. Patil Vidyapeeth) for providing valuable support to publish our research article entitled “Evaluating the Prevalence and Predictors of Thyroid Dysfunction in Patients with Type 2 Diabetes Mellitus”.[1] We are equally indebted by the insights provided by the reviewers for making this manuscript of the article further constructive. In response to the comments of the appreciate, we would like to clarify key aspects of our study. We totally agree with the view of reviewer that the cross-sectional design of our study limits the ability to establish causal relationships between type 2 diabetes mellitus (T2DM) and thyroid dysfunction. As stated in our manuscript, the primary objective was to estimate prevalence and identify clinical predictors rather than to infer causality. Nonetheless, the observed association supports existing evidence suggesting a close interplay between insulin resistance, adiposity, chronic inflammation, and dysregulation of the hypothalamic–pituitary–thyroid axis.[2] Prospective longitudinal studies are indeed required to further elucidate these temporal and mechanistic relationships. The issue of thyroid screening in patients with T2DM, as highlighted by the correspondents, is of significant clinical importance. Current guidelines largely recommend selective screening based on clinical suspicion or high-risk features. However, growing evidence indicates that subclinical thyroid dysfunction in patients with T2DM may be associated with adverse cardiovascular and glycemic outcomes.[3] In our study, a higher prevalence of thyroid dysfunction was observed among older patients and those with multiple cardiometabolic risk factors, suggesting that targeted screening in such high-risk subgroups may be justified. We also acknowledge concerns regarding the lack of uniform laboratory screening standards and the cost-effectiveness of routine screening, particularly in low- and middle-income countries. Recent evidence from resource-limited settings indicates that structured thyroid screening in patients with T2DM may be feasible and cost-effective.[4] Our findings contribute region-specific data from the Nepalese population and support the need for context-adapted screening strategies rather than a universal approach. Early detection and appropriate management of thyroid dysfunction are essential to reducing long-term metabolic and cardiovascular complications.[5] Integrating thyroid risk stratification into routine diabetes care pathways may improve comprehensive endocrine management and patient outcomes. We believe that our study adds to the growing body of evidence supporting further prospective research and may inform future guideline development. We once again thank the reviewers for their valuable comments and the Editor for facilitating this academic exchange. Sincerely yours, Dr. Viyatprajna Acharya Prof and HOD, Biochemistry KIMS and PBH, KIIT DU, Bhubaneswar E-mail:[email protected] Contact No. 9078413482 Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.